feed,title,long_url,short_url
Benzinga,Hutchmed's Stock Rises After EMA Validates Surufatinib Application For Neuroendocrine Tumors,https://benzinga.com/general/biotech/21/07/22013687/hutchmeds-stock-rises-after-ema-validates-surufatinib-application-for-neuroendocrine-tumors,https://j.mp/3Bc7ZAY
